-
Patent Agency Ranking
1.发明授权Composition for preventing or treating autoimmune disease, comprising, as active ingredient, PINK1 protein or polynucleotide encoding same 有权用于预防或治疗自身免疫性疾病的组合物，其包含PINK1蛋白或编码其的多核苷酸作为活性成分公开(公告)号：US09585945B2
公开(公告)日：2017-03-07
申请号：US14948095
申请日：2015-11-20
Inventor： Mi-La Cho , Hyang-Suk Rhim , Seon-Yeong Lee , Yeong-Mi Mun , Hye-Jin Son , Eun-Ji Yang , Eun-Kyung Kim
CPC classification number: A61K38/45 , A61K48/005 , C12N9/12 , C12Y207/11001
Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.
Abstract translation: 本发明涉及用于预防或治疗自身免疫疾病的组合物，其包含作为活性成分的PINK1蛋白或编码该组合物的多核苷酸。 根据本发明的PINK1蛋白抑制Th17的活性，促进调节性T细胞（Treg）的活性，并增加Treg细胞中的自噬，由此控制过度的免疫应答。 因此，可以将PINK1蛋白质有效地用作药物组合物或免疫抑制剂，其能够预防或治疗由各种免疫反应失调引起的自身免疫疾病如关节炎等。
-
公开(公告)号：US09700531B2
公开(公告)日：2017-07-11
申请号：US14663235
申请日：2015-03-19
Inventor： Mi-La Cho , Seon-Yeong Lee , Eun-Ji Yang , Hye-Jin Son , Eun-Kyung Kim , Jun-Geol Ryu
IPC: A61K31/155 , A61K38/17 , A61K39/395 , A61P37/02 , A61K45/06
CPC classification number: A61K31/155 , A61K38/1793 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.
-
3.发明申请COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS 审中-公开使用METFORMIN预防或治疗包括LUPUS的免疫疾病的组合物公开(公告)号：US20150238445A1
公开(公告)日：2015-08-27
申请号：US14428920
申请日：2013-09-06
Inventor： Mi-La Cho , Seon-Yeong Lee , Min-Jung Park , Jae-Seon Lee , Eun-Ji Yang , Eun-Kyung Kim , Jun-Geol Ryu , Hye-Jin Son
IPC: A61K31/155
CPC classification number: A61K31/155
Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.
Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性来预防或治疗免疫疾病的组合物。 更具体地，本发明涉及包含二甲双胍化合物或其药学上可接受的盐作为预防或治疗免疫疾病的活性成分的组合物，其中所述组合物的特征在于抑制或降低作为疾病原因的B细胞活性 。 本发明在各种自身免疫性疾病中作为免疫抑制剂的用途是有价值的，该免疫抑制剂可以通过抑制或降低作为疾病原因的B细胞活性和Th17细胞活性或通过促进或增加调节性T细胞来预防或治疗免疫疾病 活动。
-
4.发明申请COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE, COMPRISING, AS ACTIVE INGREDIENT, PINK1 PROTEIN OR POLYNUCLEOTIDE ENCODING SAME 有权用于预防或治疗自身免疫疾病的组合物，包含作为活性成分，PINK1蛋白或编码其的多核苷酸公开(公告)号：US20160114007A1
公开(公告)日：2016-04-28
申请号：US14948095
申请日：2015-11-20
Inventor： Mi-La Cho , Hyang-Suk Rhim , Seon-Yeong Lee , Yeong-Mi Mun , Hye-Jin Son , Eun-Ji Yang , Eun-Kyung Kim
IPC: A61K38/45
CPC classification number: A61K38/45 , A61K48/005 , C12N9/12 , C12Y207/11001
Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.
Abstract translation: 本发明涉及用于预防或治疗自身免疫疾病的组合物，其包含作为活性成分的PINK1蛋白或编码该组合物的多核苷酸。 根据本发明的PINK1蛋白抑制Th17的活性，促进调节性T细胞（Treg）的活性，并增加Treg细胞中的自噬，从而控制过度的免疫应答。 因此，可以将PINK1蛋白质有效地用作药物组合物或免疫抑制剂，其能够预防或治疗由各种免疫反应失调引起的自身免疫疾病如关节炎等。
-
5.发明申请COMPOSITION COMPRISING METFORMIN AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE 有权包含METFORMIN作为活性成分用于预防或治疗炎症性皮肤疾病的组合物公开(公告)号：US20150196511A1
公开(公告)日：2015-07-16
申请号：US14663235
申请日：2015-03-19
Inventor： Mi-La Cho , Seon-Yeong Lee , Eun-Ji Yang , Hye-Jin Son , Eun-Kyung Kim , Jun-Geol Ryu
IPC: A61K31/155 , A61K39/395
CPC classification number: A61K31/155 , A61K38/1793 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.
Abstract translation: 本发明涉及包含二甲双胍作为预防或治疗炎症性肠病的活性成分的组合物。 根据本发明的二甲双胍化合物或二甲双胍 - 依那西普（商品名：恩布雷）复合物可以具有保持小肠厚度和大肠长度正常，抑制或降低IL-17活性和 TNF-α，并且促进或增加IFNr的活性，因此可以有效地用作预防或治疗包括炎性肠病的自身免疫性疾病的药物组合物。
-
-
-
-
Search Results
5
records
(took 0.017 seconds)
